Allavena P, Grandi M, D'Incalci M, Geri O, Giuliani F C, Mantovani A
Int J Cancer. 1987 Jul 15;40(1):104-7. doi: 10.1002/ijc.2910400119.
Two human cell lines, the colon carcinoma Lovo and the transformed intestinal I-407, and their variants (Lovo/Dx and I-407/Dx), with pleiotropic resistance to cancer chemotherapeutic drugs, were examined for their susceptibility to human Interleukin-2-activated killer cells and to activated monocytes. These non-specific or broadly specific effector cells expressed cytotoxicity levels on pleiotropically resistant tumor cells comparable to those of the parental cell populations. This finding provides a rationale for immunological approaches designed to eradicate residual tumor cells surviving and resistant to cytotoxic chemotherapy.
对两种人类细胞系，即结肠癌细胞系Lovo和转化的肠细胞系I - 407及其变体（Lovo/Dx和I - 407/Dx）进行了研究，这些细胞系对癌症化疗药物具有多药耐药性，检测它们对人白细胞介素-2激活的杀伤细胞和激活的单核细胞的敏感性。这些非特异性或广泛特异性的效应细胞对多药耐药肿瘤细胞表达的细胞毒性水平与亲代细胞群体相当。这一发现为旨在根除在细胞毒性化疗后存活且耐药的残留肿瘤细胞的免疫治疗方法提供了理论依据。
